Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors

Peng Yang, Kyaw Zeyar Myint, Qin Tong, Rentian Feng, Haiping Cao, Abdulrahman A. Almehizia, Mohammed Hamed Alqarni, Lirong Wang, Patrick Bartlow, Yingdai Gao, Jürg Gertsch, Jumpei Teramachi, Noriyoshi Kurihara, G. David Roodman, Tao Cheng, Xiang Qun Xie

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

N,N′-((4-(Dimethylamino)phenyl)methylene)bis(2-phenylacetamide) was discovered by using 3D pharmacophore database searches and was biologically confirmed as a new class of CB2 inverse agonists. Subsequently, 52 derivatives were designed and synthesized through lead chemistry optimization by modifying the rings A-C and the core structure in further SAR studies. Five compounds were developed and also confirmed as CB2 inverse agonists with the highest CB2 binding affinity (CB2Ki of 22-85 nM, EC50 of 4-28 nM) and best selectivity (CB 1/CB2 of 235- to 909-fold). Furthermore, osteoclastogenesis bioassay indicated that PAM compounds showed great inhibition of osteoclast formation. Especially, compound 26 showed 72% inhibition activity even at the low concentration of 0.1 μM. The cytotoxicity assay suggested that the inhibition of PAM compounds on osteoclastogenesis did not result from its cytotoxicity. Therefore, these PAM derivatives could be used as potential leads for the development of a new type of antiosteoporosis agent.

Original languageEnglish
Pages (from-to)9973-9987
Number of pages15
JournalJournal of Medicinal Chemistry
Volume55
Issue number22
DOIs
StatePublished - Nov 26 2012

Fingerprint

Cannabinoid Receptor CB2
Osteoclasts
Osteogenesis
Biological Assay
Databases
Lead
2-phenylacetamide
3-(5-nitrofuryl)-7-(5-nitrofurfurylidene)-3,3a,4,5,6,7-hexahydro-2H-indazole

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors. / Yang, Peng; Myint, Kyaw Zeyar; Tong, Qin; Feng, Rentian; Cao, Haiping; Almehizia, Abdulrahman A.; Alqarni, Mohammed Hamed; Wang, Lirong; Bartlow, Patrick; Gao, Yingdai; Gertsch, Jürg; Teramachi, Jumpei; Kurihara, Noriyoshi; Roodman, G. David; Cheng, Tao; Xie, Xiang Qun.

In: Journal of Medicinal Chemistry, Vol. 55, No. 22, 26.11.2012, p. 9973-9987.

Research output: Contribution to journalArticle

Yang, P, Myint, KZ, Tong, Q, Feng, R, Cao, H, Almehizia, AA, Alqarni, MH, Wang, L, Bartlow, P, Gao, Y, Gertsch, J, Teramachi, J, Kurihara, N, Roodman, GD, Cheng, T & Xie, XQ 2012, 'Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors', Journal of Medicinal Chemistry, vol. 55, no. 22, pp. 9973-9987. https://doi.org/10.1021/jm301212u
Yang, Peng ; Myint, Kyaw Zeyar ; Tong, Qin ; Feng, Rentian ; Cao, Haiping ; Almehizia, Abdulrahman A. ; Alqarni, Mohammed Hamed ; Wang, Lirong ; Bartlow, Patrick ; Gao, Yingdai ; Gertsch, Jürg ; Teramachi, Jumpei ; Kurihara, Noriyoshi ; Roodman, G. David ; Cheng, Tao ; Xie, Xiang Qun. / Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors. In: Journal of Medicinal Chemistry. 2012 ; Vol. 55, No. 22. pp. 9973-9987.
@article{e6c6970334734c678c5987f7b476fb16,
title = "Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors",
abstract = "N,N′-((4-(Dimethylamino)phenyl)methylene)bis(2-phenylacetamide) was discovered by using 3D pharmacophore database searches and was biologically confirmed as a new class of CB2 inverse agonists. Subsequently, 52 derivatives were designed and synthesized through lead chemistry optimization by modifying the rings A-C and the core structure in further SAR studies. Five compounds were developed and also confirmed as CB2 inverse agonists with the highest CB2 binding affinity (CB2Ki of 22-85 nM, EC50 of 4-28 nM) and best selectivity (CB 1/CB2 of 235- to 909-fold). Furthermore, osteoclastogenesis bioassay indicated that PAM compounds showed great inhibition of osteoclast formation. Especially, compound 26 showed 72{\%} inhibition activity even at the low concentration of 0.1 μM. The cytotoxicity assay suggested that the inhibition of PAM compounds on osteoclastogenesis did not result from its cytotoxicity. Therefore, these PAM derivatives could be used as potential leads for the development of a new type of antiosteoporosis agent.",
author = "Peng Yang and Myint, {Kyaw Zeyar} and Qin Tong and Rentian Feng and Haiping Cao and Almehizia, {Abdulrahman A.} and Alqarni, {Mohammed Hamed} and Lirong Wang and Patrick Bartlow and Yingdai Gao and J{\"u}rg Gertsch and Jumpei Teramachi and Noriyoshi Kurihara and Roodman, {G. David} and Tao Cheng and Xie, {Xiang Qun}",
year = "2012",
month = "11",
day = "26",
doi = "10.1021/jm301212u",
language = "English",
volume = "55",
pages = "9973--9987",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "22",

}

TY - JOUR

T1 - Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors

AU - Yang, Peng

AU - Myint, Kyaw Zeyar

AU - Tong, Qin

AU - Feng, Rentian

AU - Cao, Haiping

AU - Almehizia, Abdulrahman A.

AU - Alqarni, Mohammed Hamed

AU - Wang, Lirong

AU - Bartlow, Patrick

AU - Gao, Yingdai

AU - Gertsch, Jürg

AU - Teramachi, Jumpei

AU - Kurihara, Noriyoshi

AU - Roodman, G. David

AU - Cheng, Tao

AU - Xie, Xiang Qun

PY - 2012/11/26

Y1 - 2012/11/26

N2 - N,N′-((4-(Dimethylamino)phenyl)methylene)bis(2-phenylacetamide) was discovered by using 3D pharmacophore database searches and was biologically confirmed as a new class of CB2 inverse agonists. Subsequently, 52 derivatives were designed and synthesized through lead chemistry optimization by modifying the rings A-C and the core structure in further SAR studies. Five compounds were developed and also confirmed as CB2 inverse agonists with the highest CB2 binding affinity (CB2Ki of 22-85 nM, EC50 of 4-28 nM) and best selectivity (CB 1/CB2 of 235- to 909-fold). Furthermore, osteoclastogenesis bioassay indicated that PAM compounds showed great inhibition of osteoclast formation. Especially, compound 26 showed 72% inhibition activity even at the low concentration of 0.1 μM. The cytotoxicity assay suggested that the inhibition of PAM compounds on osteoclastogenesis did not result from its cytotoxicity. Therefore, these PAM derivatives could be used as potential leads for the development of a new type of antiosteoporosis agent.

AB - N,N′-((4-(Dimethylamino)phenyl)methylene)bis(2-phenylacetamide) was discovered by using 3D pharmacophore database searches and was biologically confirmed as a new class of CB2 inverse agonists. Subsequently, 52 derivatives were designed and synthesized through lead chemistry optimization by modifying the rings A-C and the core structure in further SAR studies. Five compounds were developed and also confirmed as CB2 inverse agonists with the highest CB2 binding affinity (CB2Ki of 22-85 nM, EC50 of 4-28 nM) and best selectivity (CB 1/CB2 of 235- to 909-fold). Furthermore, osteoclastogenesis bioassay indicated that PAM compounds showed great inhibition of osteoclast formation. Especially, compound 26 showed 72% inhibition activity even at the low concentration of 0.1 μM. The cytotoxicity assay suggested that the inhibition of PAM compounds on osteoclastogenesis did not result from its cytotoxicity. Therefore, these PAM derivatives could be used as potential leads for the development of a new type of antiosteoporosis agent.

UR - http://www.scopus.com/inward/record.url?scp=84870047476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870047476&partnerID=8YFLogxK

U2 - 10.1021/jm301212u

DO - 10.1021/jm301212u

M3 - Article

C2 - 23072339

AN - SCOPUS:84870047476

VL - 55

SP - 9973

EP - 9987

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 22

ER -